Sun Pharmaceutical Industries Ltd (SUNPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sun Pharmaceutical Industries Ltd on NSE and BSE, with an AI summary of each filing.
Q2FY27 Earnings Call Transcript
Transcript · 05 Nov 2026, 12:49 am
Clarification regarding news report relating to the Company''s Assam facility
Others (Uncategorized) · 03 Nov 2026, 2:28 am
Sun Pharma Clarifies News Report on Assam Facility and Share Price Movement Sun Pharmaceutical Industries clarified that news reports regarding halted eye-care drug production at its Assam facility stem from developments in Aug'26 rather than any new event on 30th Oct'26. The company noted the matter did not warrant a Regulation 30 disclosure when assessed. Sun Pharma also stated it cannot attribute recent share price fluctuations to the report or any specific factor, noting Q2/H1 FY27 financial results were announced on 30th Oct'26, and confirmed no undisclosed material events exist.
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting ....
Others (Uncategorized) · 02 Nov 2026, 7:53 pm
Completion and results of postal ballot dated 01 October 2026
Others (Uncategorized) · 01 Nov 2026, 1:44 am
Sun Pharma Shareholders Approve ESOP 2026, Enhanced Borrowing, and Investment Limits Sun Pharmaceutical Industries announced the approval of all special resolutions via postal ballot concluded on 31st Oct'26. Shareholders approved the Sun Pharma Employees Stock Option Plan 2026 ("ESOP 2026"), including trust funding, secondary share acquisitions, and scheme extension to subsidiary employees. Additionally, members cleared key capital-structuring resolutions, including enhanced investment and lending limits under Section 186, expanded borrowing limits under Section 180(1)(c), creation of security under Section 180(1)(a) of the Companies Act, 2013, and creation of encumbrances over shares pursuant to SEBI Listing Regulations.
Q2FY27- Investor Call Audio Recording
Audio / Video · 31 Oct 2026, 1:48 am
Sun Pharma Releases Q2FY27 Earnings Call Audio Recording Sun Pharmaceutical Industries has made available the audio recording of its Q2FY27 earnings call held on 30th Oct'26. In compliance with Regulation 30 of SEBI LODR Regulations, the recording has been uploaded to the company's official website for investor access.
Board Meeting Outcome - Conclusion
Outcome · 30 Oct 2026, 8:47 pm
Sun Pharma Appoints Deloitte Haskins & Sells as Statutory Auditors Sun Pharmaceutical Industries approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as statutory auditors for a five-year term, subject to shareholder approval. The mandate begins from the conclusion of the FY27 AGM and runs until the FY32 AGM. Deloitte replaces incumbent auditor S R B C & CO LLP, which completes its mandatory two consecutive five-year terms at the FY27 AGM in compliance with Section 139(2) of the Companies Act, 2013.
Unaudited Financial Results for the quarter and half year ended 30 September 2026
Outcome · 30 Oct 2026, 7:45 pm
Unaudited Financial Results for the quarter and half year ended 30 September 2026
Financial Result · 30 Oct 2026, 7:44 pm
Sun Pharmaceutical Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 1,61,987 (+11.9% YoY | +5.9% QoQ) ■ EBITDA: 47,439 (+4.8% YoY | +7.4% QoQ) ■ EBITDA Margin (%): 29.3 (-198 bps YoY | +41 bps QoQ) ■ PAT: 19,885 (-36.2% YoY | -31.3% QoQ) ■ EPS (INR): 8.30 (-36.2% YoY | -31.4% QoQ)
ILUMYA (tildrakizumab-asmm) approved in the U.S. for the treatment of adults with active Psoriatic Arthritis
Press Release · 30 Oct 2026, 1:35 pm
US FDA Approves Sun Pharma's ILUMYA for Active Psoriatic Arthritis On 30th Oct'26, Sun Pharma announced that the US FDA approved its supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis (PsA). Supported by Phase 3 INSPIRE-1 and INSPIRE-2 trials, this approval expands ILUMYA's label beyond moderate-to-severe plaque psoriasis, targeting an estimated addressable population of ~2.4m Americans living with PsA. The IL-23 inhibitor is administered exclusively by healthcare providers, strengthening Sun Pharma's high-growth global innovative medicines portfolio, which currently accounts for ~20% of company sales.
Allotment of Non-convertible securities (NCDs) on Private Placement basis
Others (Uncategorized) · 26 Oct 2026, 6:00 pm
Sun Pharma Allots INR 7,816 Crore NCDs via Private Placement Sun Pharmaceutical Industries completed the private placement allotment of rated, listed, unsecured, redeemable NCDs aggregating to INR 7,816 crore on 26th Oct'26. The issue comprises Series A NCDs worth INR 2,003 crore at an 8.05% p.a. coupon with a put option on 27th Mar'28, and Series B NCDs worth INR 5,813 crore at an 8.20% p.a. coupon. Both series mature on 27th Oct'31. The base issue of INR 7,000 crore was fully subscribed, with INR 816 crore retained via the greenshoe option.
Press Release
Press Release · 23 Oct 2026, 11:31 pm
Sun Pharma Presents Robust Long-Term UNLOXCYT Data at ESMO 2026 Sun Pharma announced updated long-term pivotal trial data for UNLOXCYT (cosibelimab-ipdl) in advanced cutaneous squamous cell carcinoma at ESMO on 24th Oct'26. In locally advanced CSCC, the drug achieved a 53.1% objective response rate (ORR) with a 34.4% complete response (CR) and a median progression-free survival (PFS) of 37.3 months. Metastatic CSCC cohorts recorded ORRs of 44.4% to 51.3% (CRs of 16.7%–20.6%). Estimated 24-month response durability ranged between 69% and 82%, alongside a favorable safety profile showing 2.9% Grade 3 immune-related adverse events.
Press Release
Press Release · 20 Oct 2026, 11:03 pm
Sun Pharma's UNLOXCYT Receives NCCN Category 2A Recommendation for Advanced Skin Cancer Sun Pharma announced on 20th Oct'26 that UNLOXCYT (cosibelimab-ipdl) has received an NCCN Category 2A recommendation for locally advanced cutaneous squamous cell carcinoma (laCSCC) in patients ineligible for curative surgery or radiation, complementing its existing '25 mCSCC designation. Pivotal trial data demonstrated a 55% objective response rate, 26% complete response rate, and under 1% high-grade immune-mediated adverse reactions, with median duration of response unreached at 24.1 months follow-up. This updated guideline designation is expected to strengthen institutional formulary adoption, payer coverage, and upfront patient access across the US.
Earnings call for the financial results of the second quarter on 30 October 2026
Intimation · 30 Oct 2026, 6:30 pm
Sun Pharma Schedules Q2 Results Announcement and Earnings Call for 30th Oct'26 Sun Pharmaceutical Industries Limited will announce its financial results for the second quarter ended 30th Sep'26 on 30th Oct'26. Senior management will host an hour-long earnings conference call on the same day at 06:30 PM IST to discuss performance and take questions. The call will be accessible via universal dial-in numbers (+91 22 6629 0049 / +91 22 7194 5729) and an audio webcast on the company's website, with pre-registration available through DiamondPass. A transcript will also be published online post-call.
Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 2026
Intimation · 30 Oct 2026, 5:30 am
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Unaudited ....
Intimation · 30 Oct 2026, 5:30 am
Sun Pharma Board Meeting Scheduled for 30th Oct'26 to Consider Q2 Results Sun Pharmaceutical Industries announced that its Board of Directors will meet on 30th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Consequently, the trading window for dealing in company securities, closed since 1st Oct'26, will remain shut until 1st Nov'26 (48 hours post-declaration of results).
Update on Credit Ratings
Others (Uncategorized) · 13 Oct 2026, 11:23 pm
Sun Pharma Receives 'AAA/Stable' Ratings for INR 15,000 Crore NCD Issue On 13th Oct'26, CRISIL and ICRA assigned 'AAA/Stable' ratings to Sun Pharma's proposed INR 15,000 crore NCD programme and reaffirmed 'A1+' on its INR 4,000 crore CP facility. The ratings factor in the proposed USD 11.75 billion acquisition of Organon & Co. Net debt to EBITDA is projected to rise temporarily to 1.5–2.0x in FY28 before deleveraging. In Q1 FY27, operating income rose ~10% YoY to INR 15,300 crore with a 29% operating margin, backed by strong growth in India and innovative medicines.
Outcome of the Board Meeting held on 12 October 2026
Change in Management · 13 Oct 2026, 1:34 am
Sun Pharma Approves Up to ₹10,000 Crore NCD Issuance; Director Resigns Sun Pharmaceutical Industries' Board approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs) on a private placement basis for up to ₹10,000 Crore in one or more tranches. The Board also authorized its Finance Committee to finalize tranche-specific terms and allotment details. Additionally, Non-Executive Independent Director Gautam Doshi resigned with immediate effect on 12th Oct'26, citing personal commitments, simultaneously stepping down from board committees and subsidiary directorships with no other material reasons reported.
Outcome of the Board Meeting held on 12 October 2026
Outcome · 13 Oct 2026, 1:26 am
Sun Pharma Approves Up to ₹10,000 Crore NCD Issuance and Announces Board Resignation Sun Pharmaceutical Industries' Board approved the issuance of listed, rated, unsecured, redeemable Non-Convertible Debentures (NCDs) on a private placement basis for an aggregate amount not exceeding INR 10,000 Crore, in one or more tranches. The Board also authorized its Finance Committee to determine tranche-specific terms, issuance, allocation, and allotment. Separately, Non-Executive Independent Director Gautam Doshi resigned with immediate effect on 12th Oct'26, citing personal commitments, consequently stepping down from all Board committees and subsidiary directorships with no other material reasons reported.
Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising.
Intimation · 08 Oct 2026, 2:17 am
Board meeting intimation for consideration and approval of the issuance of listed, rated, unsecured, redeemable, non-convertible debentures
Intimation · 08 Oct 2026, 2:09 am
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/10/2026 ,inter alia, to consider and approve the issuance ....
Intimation · 08 Oct 2026, 2:09 am
Sun Pharma Board to Consider Raising up to INR 15,000 Crore via NCDs Sun Pharmaceutical Industries Limited has scheduled a Board of Directors meeting on 12th Oct'26 to consider and approve the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs). The planned fundraise will be executed in one or more tranches on a private placement basis for an aggregate amount not exceeding INR 15,000 Crore.
Press Release
Press Release · 06 Oct 2026, 11:52 pm
Sun Pharma Funds $2.5 Million Dermatology Professorship at Mount Sinai Sun Pharma announced on 6th Oct'26 the establishment of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai, supported by a $2.5 million endowment. The perpetual endowment funds research, clinical education, and mentorship, with Dr. Mark G. Lebwohl installed as the inaugural professor. As the second-largest U.S. pharmaceutical dermatology company by prescription volume, Sun Pharma reinforces its strategic focus on specialty dermatology, with its Global Innovative Medicines portfolio contributing roughly 22% of total company sales across key therapeutic segments.
Press Release is enclosed
Press Release · 01 Oct 2026, 11:16 pm
Sun Pharma Announces Positive Two-Year LEQSELVI Data in Severe Alopecia Areata Sun Pharma presented two-year open-label extension data for LEQSELVI (deuruxolitinib 8 mg BID) at the EADV Congress on 1st Oct'26, showing sustained efficacy and consistent safety in severe alopecia areata. Among baseline responders, 93.9% maintained response (SALT score ≤20) through Week 108. Of initial nonresponders achieving response at Week 52, 96.8% maintained efficacy through Week 108. Safety remained consistent with earlier trials, showing mostly mild-to-moderate adverse events and no deaths, thrombosis, or major adverse cardiovascular events at the FDA-approved dosage.
ESG Overview for FY 2025-26
Others (Uncategorized) · 30 Sept 2026, 12:52 am